EP1246804A1 - Cristaux de 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoleine utilises en tant qu'inhibiteurs de cetp - Google Patents

Cristaux de 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoleine utilises en tant qu'inhibiteurs de cetp

Info

Publication number
EP1246804A1
EP1246804A1 EP00971662A EP00971662A EP1246804A1 EP 1246804 A1 EP1246804 A1 EP 1246804A1 EP 00971662 A EP00971662 A EP 00971662A EP 00971662 A EP00971662 A EP 00971662A EP 1246804 A1 EP1246804 A1 EP 1246804A1
Authority
EP
European Patent Office
Prior art keywords
crystal
formula
trιfluoromethyl
recited
dιhydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00971662A
Other languages
German (de)
English (en)
Inventor
Douglas J. M. Pfizer Global Rch. & Dev. ALLEN
Troy A. Pfizer Global Rch. & Dev. APPLETON
Lyle R. Pfizer Global Rch. & Dev. BROSTROM
Derek L. Pfizer Global Rch. & Dev. TICKNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of EP1246804A1 publication Critical patent/EP1246804A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Definitions

  • This invention relates to cholesteryl ester transfer protein (CETP) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein (HDL)- cholesterol and to lower certain other plasma lipid levels, such as low density lipoprotein (LDL)-cholesterol and triglycendes and accordingly to treat diseases which are affected by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycendes, such as atherosclerosis and cardiovascular diseases in certain mammals (i.e., those which have CETP in their plasma), including humans.
  • CETP cholesteryl ester transfer protein
  • this invention relates to CETP inhibitor crystals, pharmaceutical compositions comprising these crystals, a process for preparing these crystals and to methods of treating atherosclerosis, obesity, and related diseases and/or conditions with the crystals.
  • Atherosclerosis and its associated coronary artery disease is the leading cause of mortality in the industrialized world.
  • CAD coronary artery disease
  • CHD coronary heart disease
  • LDL-cholesterol may be the most recognized form of dyslipidemia, it is by no means the only significant lipid associated contributor to CHD.
  • Low HDL-cholesterol is also a known risk factor for CHD (Gordon, D.J., et al ,' "High-density Lipoprotein Cholesterol and Cardiovascular Disease", Circulation, (1989), 79 8-15)
  • dyslipidemia is not a unitary risk profile for CHD but may be comprised of one or more lipid aberrations
  • cholesteryl ester transfer protein activity affects all three.
  • the net result of CETP activity is a lowering of HDL cholesterol and an increase in LDL cholesterol This effect on lipoprotein profile is believed to be pro-atherogenic, especially in subjects whose lipid profile constitutes an increased risk for CHD.
  • Another aspect of this invention is directed to an anhydrous crystal of Formula
  • Another aspect of this invention is directed to the corresponding anhydrous crystal having the X-ray powder diffraction pattern as shown in Figure 1
  • Another aspect of this invention is directed to an ethanolate crystal of Formula I
  • Another aspect of this invention is directed to the corresponding ethanolate crystal having the X-ray powder diffraction pattern as shown in Figure 2
  • a preferred dosage is about 0 01 to 100 mg/kg/day of a Formula I crystal
  • An especially preferred dosage is about 0 1 to 10 mg/kg/day of a Formula I crystal
  • compositions, combinations and kits reference is made to a crystal of Formula I While it is understood that if the crystal is in solution, the crystal form is not present (in contrast to e g , a dry tablet formulation), the following methods pharmaceutical compositions combinations and kits are intended to include a method or formulation resulting from a use of such crystal (e.g., administering a gelatin capsule including an oil formulation solution of the crystal).
  • Yet another aspect of this invention is directed to methods for treating atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypert ⁇ glyce ⁇ demia, fami al- hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia in a mammal (including a human being either male or female) by administering to a mammal in need of such treatment an atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypert ⁇ glyceridemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications
  • Yet another aspect of this invention is directed to a method for treating atherosclerosis in a mammal (including a human being) by administering to a mammal in need of such treatment an atherosclerosis treating amount of a Formula I crystal
  • Yet another aspect of this invention is directed to a method for treating peripheral vascular disease in a mammal (including a human being) by administering to a mammal in need of such treatment a peripheral vascular disease treating amount of a Formula I crystal.
  • Yet another aspect of this invention is directed to a method for treating dyslipidemia in a mammal (including a human being) by administering to a mammal in need of such treatment a dyslipidemia treating amount of a Formula I crystal.
  • Yet another aspect of this invention is directed to a method for treating hyperbetalipoproteinemia in a mammal (including a human being) by administering to a mammal in need of such treatment a hyperbetalipoproteinemia treating amount of a Formula I crystal.
  • Yet another aspect of this invention is directed to a method for treating hypoalphalipoproteinemia in a mammal (including a human being) by administering to a mammal in need of such treatment a hypoalphalipoproteinemia treating amount of a Formula I crystal
  • Yet another aspect of this invention is directed to a method for treating hypercholesterolemia in a mammal (including a human being) by administering to a mammal in need of such treatment a hypercholesterolemia treating amount of a Formula I crystal
  • Yet another aspect of this invention is directed to a method for treating hypertriglyce ⁇ demia in a mammal (including a human being) by administering to a mammal in need of such treatment a hypert ⁇ glyceridemia treating amount of a Formula I crystal
  • Yet another aspect of this invention is directed to a method for treating fami al-hypercholesterolemia in a mammal (including a human being) by administering to a mammal in need of such treatment a fami al- hypercholesterolemia treating amount of a Formula I crystal
  • Yet another aspect of this invention is directed to a method for treating cardiovascular disorders in a mammal (including a human being) by administering to a mammal in need of such treatment a cardiovascular disorder treating amount of a Formula I crystal
  • Yet another aspect of this invention is directed to a method for treating angina in a mammal (including a human being) by administering to a mammal in need of such treatment an angina treating amount of a Formula I crystal
  • Yet another aspect of this invention is directed to a method for treating ischemia in a mammal (including a human being) by administering to a mammal in need of such treatment an ischemic disease treating amount of a Formula I crystal
  • Yet another aspect of this invention is directed to a method for treating cardiac ischemia in a mammal (including a human being) by administering to a mammal in need of such treatment a cardiac ischemic treating amount of a Formula I crystal
  • Yet another aspect of this invention is directed to a method for treating stroke in a mammal (including a human being) by administering to a mammal in need of such treatment a stroke treating amount of a Formula I crystal
  • Yet another aspect of this invention is directed to a method for treating a myocardial infarction in a mammal (including a human being) by administering to a mammal in need of such treatment a myocardial infarction treating amount of a Formula I crystal
  • Yet another aspect of this invention is directed to a method for treating reperfusion injury in a mammal (including a human being) by administering to a mammal in need of such treatment a reperfusion injury treating amount of a Formula I crystal.
  • Yet another aspect of this invention is directed to a method for treating angioplastic restenosis in a mammal (including a human being) by administering to a mammal in need of such treatment an angioplastic restenosis treating amount of a Formula I crystal.
  • Yet another aspect of this invention is directed to a method for treating hypertension in a mammal (including a human being) by administering to a mammal in need of such treatment a hypertension treating amount of a Formula I crystal
  • Yet another aspect of this invention is directed to a method for treating the vascular complications of diabetes in a mammal (including a human being) by administering to a mammal in need of such treatment a vascular complications of diabetes treating amount of a Formula I crystal.
  • Yet another aspect of this invention is directed to a method for treating obesity in a mammal (including a human being) by administering to a mammal in need of such treatment an obesity treating amount of a Formula I crystal.
  • Yet another aspect of this invention is directed to a method for treating endotoxemia in a mammal (including a human being) by administering to a mammal in need of such treatment an endotoxemia treating amount of a Formula I crystal.
  • This invention is also directed to pharmaceutical compositions which comprise a therapeutically effective amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent.
  • This invention is also directed to pharmaceutical compositions for the treatment of atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyce ⁇ demia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia in a mammal (including a human being) which comprise a therapeutically effective amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent.
  • This invention is also directed to pharmaceutical compositions for the treatment of atherosclerosis in a mammal (including a human being) which comprise an atherosclerosis treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
  • compositions for the treatment of dyslipidemia in a mammal which comprise a dyslipidemia treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
  • compositions for the treatment of hyperbetalipoproteinemia in a mammal which comprise a hyperbetalipoproteinemia treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
  • compositions for the treatment of hypoalphalipoproteinemia in a mammal which comprise a hypoalphalipoproteinemia treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
  • This invention is also directed to pharmaceutical compositions for the treatment of hypercholesterolemia in a mammal (including a human being) which comprise a hypercholesterolemia treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
  • This invention is also directed to pharmaceutical compositions for the treatment of hypert ⁇ glyceridemia in a mammal (including a human being) which comprise a hypertriglyce ⁇ demia treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
  • compositions for the treatment of familial-hypercholesterolemia in a mammal which comprise a familial-hypercholesterolemia treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
  • compositions for the treatment of angina in a mammal which comprise an angma treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
  • compositions for the treatment of ischemia in a mammal which comprise an ischemic treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
  • compositions for the treatment of cardiac ischemia in a mammal which comprise a cardiac ischemic treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
  • This invention is also directed to pharmaceutical compositions for the treatment of stroke in a mammal (including a human being) which comprise a stroke treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
  • pharmaceutical compositions for the treatment of a myocardial infarction in a mammal (including a human being) which comprise a myocardial infarction treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
  • compositions for the treatment of reperfusion injury in a mammal which comprise a reperfusion injury treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
  • compositions for the treatment of angioplastic restenosis in a mammal which comprise an angioplastic restenosis treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
  • compositions for the treatment of hypertension in a mammal which comprise a hypertension treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
  • This invention is also directed to pharmaceutical compositions for the treatment of the vascular complications of diabetes in a mammal (including a human being) which comprise a vascular complications of diabetes treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
  • pharmaceutical compositions for the treatment of obesity in a mammal (including a human being) which comprise an obesity treating amount of a crystal of Formula I and a pharmaceutically acceptable carrier, vehicle or diluent
  • This invention is also directed to a pharmaceutical combination composition
  • a pharmaceutical combination composition comprising a therapeutically effective amount of a composition comprising a first compound, said first compound being a Formula I crystal, a second compound, said second compound being an HMG-CoA reductase inhibitor, an microsomal t ⁇ giyceride transfer protein (MTP)/Apo B secretion inhibitor, a PPAR activator, a bile acid reuptake inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacm, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant, and/or optionally a pharmaceutical carrier, vehicle or diluent
  • HMG-CoA reductase inhibitor Preferred among the second compounds are an HMG-CoA reductase inhibitor and a MTP/Apo B secretion inhibitor
  • a particularly preferred HMG-CoA reductase inhibitor is lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin or ⁇ vastatin
  • Another aspect of this invention is a method for treating atherosclerosis in a mammal comprising administering to a mammal suffering from atherosclerosis a first compound, said first compound being a Formula I crystal, and a second compound, said second compound being an HMG-CoA reductase inhibitor, an MTP/Apo B secretion inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacm, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant wherein the amounts of the first and second compounds result in a therapeutic effect
  • the second compound is an HMG-CoA reductase inhibitor or an MTP/Apo B secretion inhibitor
  • kits comprising a a first compound, said first compound being a Formula I crystal, and a pharmaceutically acceptable carrier in a first in a unit dosage form, b a second compound, said second compound being an HMG CoA reductase inhibitor, an MTP/Apo B secretion inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacm, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant and a pharmaceutically acceptable carrier in a second unit dosage form, and c means for containing said first and second dosage forms wherein the amounts of the first and second compounds result in a therapeutic effect
  • a preferred second compound is an HMG-CoA reductase inhibitor or an MTP/Apo B secretion inhibitor
  • a particularly preferred HMG-CoA reductase inhibitor is lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin or nvastatin
  • the present invention is also directed to processes for preparing crystalline anhydrous [2R.4S] 4-[(3,5-b ⁇ s-tr ⁇ fluoromethyl-benzyl)-methoxycarbonyl-am ⁇ no]-2- ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester by dissolving or mixing [2R,4S] 4-[(3,5-b ⁇ s-t ⁇ fluoromethyl-benzyl)-methoxycarbonyl- am ⁇ no]-2-ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl este
  • Another aspect of this invention is directed to a process for preparing crystalline ethanolate [2R.4S] 4-[(3,5-b ⁇ s-tr ⁇ fluoromethyl-benzyl)-methoxycarbonyl- am ⁇ no]-2-ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester by dissolving or mixing [2R,4S] 4-[(3,5-b ⁇ s-tr ⁇ fluoromethyl-benzyl)-methoxycarbonyl- am ⁇ no]-2-ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester in ethanol/water at ambient temperature for about 0 5 to about 18 hours
  • ethanol is used without water
  • This invention is also directed to a process for preparing crystalline anhydrous [2R,4S] 4-[(3,5-b ⁇ s-t ⁇ fluoromethyl-benzyl)-methoxycarbonyl-am ⁇ no]-2-ethyl-6- t ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester comprising dissolving or mixing [2R,4S] 4-[3,5-b ⁇ s-tr ⁇ fluoromethyl-benzyl)-methoxycarbonyl- am ⁇ no]-2-ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester in ethanol at ambient temperature for about 2 to about 24 hours It is noted that as the anhydrous and ethanolate crystals are of different energy levels seeding with either anhydrous or ethanolate may determine the resulting isolated
  • mammals is meant to refer to all mammals which contain CETP in their plasma, for example, rabbits and primates such as monkeys and humans. Certain other mammals e.g., dogs, cats, cattle, goats, sheep and horses do not contain CETP in their plasma and so are not included herein.
  • ethanolate refers to an ethanol of solvation
  • treating includes preventative (e.g., prophylactic) and palliative treatment.
  • pharmaceutically acceptable it is meant the carrier, vehicle, diluent, excipients, and/or salt must be compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof.
  • reaction-inert solvent and “inert solvent” refers to a solvent or mixture of solvents which does not interact with starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product.
  • the compound of this invention can exist in radiolabelled form, i.e., said compound may contain one or more atoms containing an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • Radioisotopes of hydrogen, carbon, phosphorous, fluorine and chlorine include 3 H, 1 C, 32 P, 35 S, 8 F and 36 CI, respectively.
  • the compound of this invention which contains those radioisotopes and/or other radioisotopes of other atoms is within the scope of this invention.
  • radiolabelled compound of this invention can generally be prepared by methods well known to those skilled in the art. Conveniently, such radiolabelled compounds can be prepared by carrying out the procedures disclosed in the Examples below by substituting a readily available radiolabelled reagent for a non-radiolabelled reagent
  • FIG. 1 is a characteristic x-ray powder diffraction pattern showing that anhydrous [2R,4S] 4-[(3,5-b ⁇ s-tr ⁇ fluoromethyl-benzyl)-methoxycarbonyl-am ⁇ no]-2- ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester is crystalline.
  • Vertical Axis Intensity (CPS); Horizontal Axis. Two theta (degrees)
  • FIG. 2 is the characteristic x-ray powder diffraction pattern of the ethanolate [2R.4S] 4-[(3,5-b ⁇ s-tr ⁇ fluoromethyl-benzyl)-methoxycarbonyl-am ⁇ no]-2-ethyl-6- tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester as crystalline Vertical Axis: Intensity (CPS); Horizontal Axis: Two theta (degrees)) Detailed Description Of The Invention
  • the compound of this invention can be made by processes which include analogous processes known in the chemical arts, particularly in light of the description contained herein. Certain processes for the manufacture of the compound of this invention are provided as further features of the invention and are described below including in the Examples.
  • An anhydrous crystalline form of the above compound may be prepared from the amorphous compound by recrystallization from hexanes (solvent comprised of hexane isomers (e.g., n-hexane, cyclohexane, methyl pentane, etc )) at a temperature of about 40°C to about 80°C, preferably 60° followed typically by granulating, for about 2 to about 24 hours, then filtering the material and subsequent air drying.
  • hexanes solvent comprised of hexane isomers (e.g., n-hexane, cyclohexane, methyl pentane, etc )
  • the anhydrous crystal may be prepared from the ethanolate crystalline form (described below) utilizing analogous procedures to the immediately preceding procedure.
  • the yield in this procedure may be enhanced by azeotroping the ethanol from the hexanes.
  • An ethanolate crystalline form of the above compound may be prepared from the amorphous compound by recrystallization from ethanol/water at a temperature of about 20°C to about 25°C, preferably ambient temperature for about 0 5 hour to about 18 hours Typically the range is about 3% to about 10% ethanol and about 90% to about 97% water. Preferably the ratio is about 10% to about 90% ethanol/water.
  • the ethanolate crystalline form may be prepared utilizing procedures analogous to those described above but using ethanol alone.
  • the filtered materials are typically granulated for about 2 hours to about 24 hours followed by air drying.
  • the compound of the instant invention is orally admmistrable and is accordingly used in combination with a pharmaceutically acceptable vehicle, carrier or diluent suitable to oral dosage forms.
  • suitable pharmaceutically-acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions.
  • the active compound will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described below.
  • the compound may be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, powders, syrups, solutions, suspensions and the like.
  • the pharmaceutical compositions may, if desired, contain additional components such as flavorants, sweeteners, excipients and the like
  • the tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin, excipients such as dicalcium phosphate, a disintegrating agent such as corn starch, potato starch, alginic acid, a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin
  • a dosage unit form is a capsule, for example a gel capsule, it may contain, in addition to or instead of materials of the above type, a liquid carrier such as a fatty glyce ⁇ de or mixtures of fatty glyce ⁇ des, such as olive oil, or MiglyolTM or CapmulTM glyce ⁇ des
  • Dosage forms may also include orral suspensions.
  • tablets may be coated with shellac, sugar or both.
  • a syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor
  • the compound of the instant invention may also be administered parenterally.
  • parenteral administration the compound may be combined with sterile aqueous or organic media to form injectable solutions or suspensions.
  • injectable solutions prepared in this manner can then be administered intravenously, intrape ⁇ toneally, subcutaneously, or intramuscularly.
  • the pharmaceutical forms suitable for injectable use include sterile solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be fluid to the extent that easy sy ⁇ ngability exists It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi They may be sterilized, for example, by filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, or by irradiating or heating the compositions where such irradiating or heating is both appropriate and compatible with the drug formulation.
  • Additional pharmaceutical formulations may include, inter alia, suppositories, subhngual tablets, topical dosage forms and the like and these may be prepared according to methods which are commonly accepted in the art. Controlled release, sustained release, and delayed release oral or parenteral compositions may be used.
  • the dosage of the compound of the instant invention which is administered will generally be varied according to principles well known in the art taking into account the severity of the condition being treated and the route of administration.
  • the compound will be administered to a warm blooded animal (such as a human, livestock or pet) so that an effective dose, usually a daily dose administered in unitary or divided portions, is received, for example a dose in the range of about 0.01 to about 100 mg/kg/day body weight, preferably about 0.1 to about 10 mg/kg/day body weight.
  • the above dosages are exemplary of the average case; there can, of course, be individual instances where higher or lower dosage ranges are merited, and such deviations are within the scope of this invention
  • [2R,4S]4-[(3,5-b ⁇ s-tr ⁇ fluoromethyl-benzyl)-methoxycarbonyl-am ⁇ no]-2-ethyl-6- t ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester was prepared in optically enriched form by resolution of the corresponding racemate, or an intermediate in its synthesis, using standard methods.
  • Example 2 (1 -Benzotr ⁇ azol-1 -yl-propyl)-(4-t ⁇ fluoromethyl-phenyl)-am ⁇ ne
  • benzot ⁇ azole 36.96 g, 310 mmol, 1.0 equiv
  • dry toluene 400 mL
  • 4-(tr ⁇ fluoromethyl)an ⁇ l ⁇ ne 39.1 mL, 310 mmol, 1.0 equiv
  • 50 mL toluene was added over one minute.
  • Example 3 c ⁇ s-(2-Ethyl-6-tr ⁇ fluoromethyl-1 ,2,3,4-tetrahvdro-qu ⁇ nol ⁇ n-4-yl)-carbam ⁇ c acid benzyl ester
  • N-vinyl- carbamic acid benzyl ester 27.66 g, 156 mmol, 1.0 equiv
  • dry toluene 500 mL
  • the mixture was filtered and the solids washed 1 x 50 mL ethyl acetate.
  • the filtrate was concentrated to approximately 250 mL. 500 mL toluene were added, and the mixture concentrated to approximately 500 mL. 500 mL n-heptane were added, the slurry was stirred 1 h, filtered through a Buchner funnel, and dried.
  • Example 4 c ⁇ s-4-Benzyloxycarbonylam ⁇ no-2-ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 - carboxylic acid ethyl ester
  • c ⁇ s-(2- ethyl-6-tr ⁇ fluoromethyl-1 ,2,3,4-tetrahydro-qu ⁇ nol ⁇ n-4-yl)-carbam ⁇ c acid benzyl ester (96.0 g, 254 mmol, 1.0 equiv), dry dichloromethane (720 mL), and dry pyndine (103 mL, 1.27 mol, 5.0 equiv).
  • Example 5 cis-4-Amino-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1 -carboxylic acid ethyl ester
  • a one liter, four neck flask under nitrogen atmosphere was charged with cis-4- benzyloxycarbonylamino-2-ethyl-6-thfluoromethyl-3,4-dihydro-2H-quinoline-1 - carboxylic acid ethyl ester (40.1 g, 89 mmol, 1.0 equiv), methanol (400 mL), and ammonium formate (14.0 g, 223 mmol, 2.5 equiv).
  • Example 7 (-H2R, 4S)-4-(3,5-B ⁇ s-tr ⁇ fluoromethyl-benzylam ⁇ no)-2-ethyl-6-t ⁇ fluoromethyl-3,4- d ⁇ hydro-2H-gu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester tosylate salt (-) (2R, 4S)-4-Am ⁇ no-2-ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester hem ⁇ -(-)-d ⁇ benzoyl-L-tartrate salt (13 0 g, 26 2 mmol, 1 0 equiv) was suspended in 1 ,2-d ⁇ chloroethane (260 mL) in a 500 mL separatory funnel.
  • the mixture was washed 1 x 65 mL 1 N NaOH, 1 x 65 mL brine, and dried (MgS0 4 ).
  • the mixture was filtered, concentrated to approximately approximately 80 mL, and transferred to a 250 mL three neck flask.
  • 3,5-B ⁇ s(tr ⁇ fluoromethyl)benzaldehyde (4.53 mL, 27.5 mmol, 1.05 equiv) was added, and the mixture stirred 1 h at room temperature under nitrogen atmosphere.
  • Sodium triacetoxyborohyd ⁇ de (11.1 g, 52.4 mmol, 2.0 equiv) was added in one portion, and the white slurry was stirred 18 h.
  • Example 8 (-H2R, 4S)-4-[(3,5-B ⁇ s-t ⁇ fluoromethyl-benzyl)-methoxycarbonyl-am ⁇ no1-2-ethyl-6- tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester mono ethanolate Na 2 CO 3 (s) (6.75 g, 63.7 mmol, 3.5 equiv) was added to a room temperature solution of (-)-(2R, 4S)-4-(3,5-b ⁇ s-tr ⁇ fluoromethyl-benzylam ⁇ no)-2-ethyl-6-tr ⁇ fluoromethyl-3,4- d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester tosylate salt (13.0 g, 18.2 mmol, 1.0 equiv) in dry THF (130 m
  • Methyl chloroformate (3.51 mL, 45.5 mmol, 2.5 equiv) was added neat, dropwise over 2 mm. After 24 h, the mixture was concentrated to 65 mL, diluted with 260 mL ethyl acetate, and transferred to a separately funnel. The mixture was washed 1 x 90 mL 1 N HCI (C0 2 evolution), 1 x 90 mL saturated aq. NaHCO 3 , 1 x 90 mL brine, and dried (MgSO 4 ). Filtration and concentration of filtrate afforded a clear oil, which was cost ⁇ pped 3 x 33 mL 2B ethanol.
  • Example 9 Anhydrous, (-)-(2R,4S)-4-[(3,5-B ⁇ s-tr ⁇ fluoromethyl-benzyl)-methoxycarbonyl-am ⁇ nol-2- ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hydro-2H-qu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester.
  • Microscopy Well formed rods and equant (fractured rods) crystals demonstrating high birefringence when viewed across the C axis. Being in the Trigonal crystal system the crystals do not demonstrate birefringence when viewed down the C axis. The crystals demonstrate a cleavage plane perpendicular to the C axis Fusion Microsocopy In Type A oil dissolution at 50°C.
  • Microscopy crystalline needles with moderate birefringence.
  • Dry clear melt at 43°C NMR shows ethanol of solvation Degree of crystal nity: highly crystalline
  • Hygroscopicity non-hygroscopic
  • Example 11 Anhydrous (-)-(2R,4S)-4-[(3,5-b ⁇ s-tr ⁇ fluromethylbenzyl)-methoxycarbonyl-am ⁇ nol-2- ethyl-6-tr ⁇ fluoromethyl-3,4-d ⁇ hvdro-2H-gu ⁇ nol ⁇ ne-1 -carboxylic acid ethyl ester.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)

Abstract

L'invention concerne des formes cristallines d'un inhibiteur de CETP de formule (I), des procédés de fabrication desdits cristaux, des procédés d'utilisation desdits cristaux ainsi que des compositions pharmaceutiques contenant lesdits cristaux.
EP00971662A 1999-11-30 2000-11-14 Cristaux de 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoleine utilises en tant qu'inhibiteurs de cetp Withdrawn EP1246804A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30
US168051P 1999-11-30
PCT/IB2000/001650 WO2001040190A1 (fr) 1999-11-30 2000-11-14 Cristaux de 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoleine utilises en tant qu'inhibiteurs de cetp

Publications (1)

Publication Number Publication Date
EP1246804A1 true EP1246804A1 (fr) 2002-10-09

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00971662A Withdrawn EP1246804A1 (fr) 1999-11-30 2000-11-14 Cristaux de 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoleine utilises en tant qu'inhibiteurs de cetp

Country Status (28)

Country Link
EP (1) EP1246804A1 (fr)
JP (1) JP2003515592A (fr)
KR (1) KR20020058057A (fr)
CN (1) CN1402711A (fr)
AP (1) AP2002002531A0 (fr)
AU (1) AU1048801A (fr)
BG (1) BG106854A (fr)
BR (1) BR0015836A (fr)
CA (1) CA2392979A1 (fr)
CO (1) CO5271716A1 (fr)
EA (1) EA200200510A1 (fr)
EC (1) ECSP003792A (fr)
EE (1) EE200200277A (fr)
GT (1) GT200000199A (fr)
HU (1) HUP0203521A2 (fr)
IL (1) IL149097A0 (fr)
IS (1) IS6338A (fr)
MA (1) MA26845A1 (fr)
MX (1) MXPA02005354A (fr)
NO (1) NO20022558L (fr)
OA (1) OA12099A (fr)
PA (1) PA8506301A1 (fr)
PE (1) PE20010904A1 (fr)
PL (1) PL355892A1 (fr)
TN (1) TNSN00231A1 (fr)
TR (1) TR200201446T2 (fr)
UY (1) UY26454A1 (fr)
WO (1) WO2001040190A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
JP2005500314A (ja) * 2001-06-21 2005-01-06 ファイザー・プロダクツ・インク コレステロールエステル転送蛋白インヒビターの自己乳化性製剤
GT200200170A (es) * 2001-09-28 2003-05-23 Preparacion de inhibidor de cetp anhidro
EP1920766B1 (fr) * 2002-02-01 2017-08-23 Bend Research, Inc Compositions pharmaceutiques de dispersions amorphes de médicaments et matériaux formant des microphases lipophiles
EP1469832B2 (fr) 2002-02-01 2016-10-26 Bend Research, Inc. Compositions pharmaceutiques de dispersions amorphes de medicaments et materiaux formant des microphases lipophiles
CN1309370C (zh) * 2002-02-01 2007-04-11 辉瑞产品公司 使用改进的喷雾干燥设备制备均匀喷雾干燥的固体非晶形药物分散体的方法
CN1289467C (zh) 2002-08-30 2006-12-13 日本烟草产业株式会社 二苄胺化合物及其药物用途
AU2003277285B2 (en) 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
DE60331873D1 (de) 2002-12-20 2010-05-06 Pfizer Prod Inc Dosierungsform enthaltend einen CETP-Hemmer und einen HMG-CoA Reduktase Hemmer
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EA200501376A1 (ru) * 2003-03-28 2006-04-28 Пфайзер Продактс Инк. Производные 1,2,4-замещённых 1,2,3,4-тетрагидро- и 1,2-дигидрохинолинов и 1,2,3,4-тетрагидрохиноксалина в качестве ингибиторов сетр для лечения атеросклероза и тучности
CA2532931A1 (fr) 2003-08-04 2005-02-10 Pfizer Products Inc. Compositions pharmaceutiques a base d'adsorbats de medicaments amorphes et de produits aptes a former des microphases lipophiles
MXPA06003927A (es) 2003-10-08 2008-02-07 Lilly Co Eli Compuestos y metodos para tratar dislipidemia.
EP1737811B1 (fr) * 2004-04-13 2016-08-10 Merck Sharp & Dohme Corp. Inhibiteurs de cetp
KR20070041452A (ko) * 2004-06-24 2007-04-18 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
WO2006033001A1 (fr) * 2004-09-23 2006-03-30 Pfizer Products Inc. Composes de quinoline
WO2006033004A1 (fr) * 2004-09-23 2006-03-30 Pfizer Products Inc. Composes de quinoline en tant qu'inhibiteurs de cetp
WO2006091674A1 (fr) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires
WO2006098394A1 (fr) * 2005-03-14 2006-09-21 Japan Tobacco Inc. Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
EP3174995B1 (fr) 2014-07-30 2020-08-19 F.Hoffmann-La Roche Ag Marqueurs génétiques pour la prédiction de la réactivité à une thérapie avec un agent d'augmentation de hdl ou d'imitation de hdl

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
AU5731098A (en) * 1997-02-03 1998-08-25 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0140190A1 *

Also Published As

Publication number Publication date
WO2001040190A1 (fr) 2001-06-07
EE200200277A (et) 2003-10-15
AP2002002531A0 (en) 2002-06-30
OA12099A (en) 2006-05-04
MXPA02005354A (es) 2002-12-11
TR200201446T2 (tr) 2002-11-21
IL149097A0 (en) 2002-11-10
UY26454A1 (es) 2001-07-31
AU1048801A (en) 2001-06-12
NO20022558D0 (no) 2002-05-29
PE20010904A1 (es) 2001-09-10
KR20020058057A (ko) 2002-07-12
BR0015836A (pt) 2002-08-06
CA2392979A1 (fr) 2001-06-07
JP2003515592A (ja) 2003-05-07
GT200000199A (es) 2002-05-23
CN1402711A (zh) 2003-03-12
CO5271716A1 (es) 2003-04-30
NO20022558L (no) 2002-05-29
HUP0203521A2 (hu) 2003-02-28
ECSP003792A (es) 2002-04-23
PL355892A1 (en) 2004-05-31
PA8506301A1 (es) 2002-08-26
TNSN00231A1 (fr) 2002-05-30
EA200200510A1 (ru) 2002-10-31
IS6338A (is) 2002-04-12
MA26845A1 (fr) 2004-12-20
BG106854A (bg) 2002-12-29

Similar Documents

Publication Publication Date Title
WO2001040190A1 (fr) Cristaux de 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoleine utilises en tant qu'inhibiteurs de cetp
EP1125929B1 (fr) Procédé de preparation de l'ester (-)-(2R,4S)-4-[(3,5-bis-trifluoromethylbenzyl)-methoxycarbonylamino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1 carboxylate d' éthyle
DE69917400T2 (de) 4-Carboxyamino-2-Methyl-1,2,3,4-Tetrahydrochinoline als CETP-Hemmer
US5112817A (en) Quinoline derivatives
DE69926582T2 (de) Anellierte 4-Carboxyamino-2-Methyl-1,2,3,4-Tetrahydrochinoline als CETP-Hemmer
DE69925845T2 (de) 4-carboxamino-2-subsitutierte-1,2,3,4-tetrahydrochinoline als cetp inhibitoren
DE60211944T2 (de) Acetylen-derivate mit mglur 5 antagonistischer wirkung
AU2005303926B2 (en) 5-substituted quinoline and isoquinoline derivatives, a method for the production thereof and their use as antiphlogistics
JP2002526477A (ja) Ｃｅｔｐ阻害剤としての４−カルボキシアミノ−２−メチル−１，２，３，４−テトラヒドロキノリン類
JP4108129B2 (ja) Ｅａａアンタゴニストとしてのテトラヒドロキノリン誘導体
JPH01157969A (ja) 置換クロマンおよび関連化合物
US5204348A (en) Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components
DE102004044680B3 (de) Alkyliden-Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate
JPH0699399B2 (ja) 新規複素環化合物およびそれを有効成分として含有する製癌剤効果増強剤
MXPA00011855A (en) Method for making (-)-(2r,4s)-4- [(3,5-bis- trifluoromethyl-benzyl)- methoxycarbonylamino]- 2-ethyl-6- trifluoromethyl-3,4-dihydro- 2h-quinoline- 1-carboxylic acid ethyl ester

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020515

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL PAYMENT 20020515;LT PAYMENT 20020515;LV PAYMENT 20020515;MK PAYMENT 20020515;RO PAYMENT 20020515;SI PAYMENT 20020515

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040602